{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:31:44Z","timestamp":1790238704262,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40264-020-01013-3","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T19:02:56Z","timestamp":1603134176000},"page":"1315-1322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Philippe","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Revet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Yrondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Degboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7056-8126","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"1013_CR1","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S2215-0366(20)30171-1","volume":"7","author":"D Gunnell","year":"2020","unstructured":"Gunnell D, Appleby L, Arensman E, Hawton K, John A, Kapur N, et al. Suicide risk and prevention during the COVID-19 pandemic. Lancet Psychiatry. 2020;7:468\u201371.","journal-title":"Lancet Psychiatry"},{"key":"1013_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2215-0366(20)30141-3","volume":"7","author":"W Kawohl","year":"2020","unstructured":"Kawohl W, Nordt C. COVID-19, unemployment, and suicide. Lancet Psychiatry. 2020;7:389\u201390.","journal-title":"Lancet Psychiatry"},{"key":"1013_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.1060","author":"MA Reger","year":"2020","unstructured":"Reger MA, Stanley IH, Joiner TE. Suicide mortality and coronavirus disease 2019: a perfect storm? JAMA Psychiatry. 2020. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.1060.","journal-title":"JAMA Psychiatry."},{"key":"1013_CR4","unstructured":"Cloroquina\/Hidroxicloroquina: precauciones y vigilancia de posibles reacciones adversas en pacientes con COVID-19. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. 2020. https:\/\/www.aemps.gob.es\/informa\/notasinformativas\/medicamentosusohumano-3\/seguridad-1\/2020-seguridad-1\/cloroquina-hidroxicloroquina-precauciones-y-vigilancia-de-posibles-reacciones-adversas-en-pacientes-con-covid-19\/. Accessed 25 June 2020"},{"key":"1013_CR5","unstructured":"M\u00e9dicaments utilis\u00e9s chez les patients atteints du COVID-19\u202f: une surveillance renforc\u00e9e des effets ind\u00e9sirables\u2014Point d\u2019information (actualis\u00e9 le 14\/05\/2020)\u2014ANSM: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. https:\/\/ansm.sante.fr\/S-informer\/Actualite\/Medicaments-utilises-chez-les-patients-atteints-du-COVID-19-une-surveillance-renforcee-des-effets-indesirables-Point-d-information-actualise-le-14-05-2020. Accessed 25 Jun 2020"},{"key":"1013_CR6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.comppsych.2013.05.010","volume":"54","author":"NPO de Ribeiro","year":"2013","unstructured":"de Ribeiro NPO, de Schier ARM, Ornelas AC, de Oliveira CM, Nardi AE, Silva AC. Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs. Compr Psychiatry. 2013;54:1185\u20139.","journal-title":"Compr Psychiatry."},{"key":"1013_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/0961203314558863","volume":"24","author":"JA Gonzalez-Nieto","year":"2015","unstructured":"Gonzalez-Nieto JA, Costa-Juan E. Psychiatric symptoms induced by hydroxychloroquine. Lupus. 2015;24:339\u201340.","journal-title":"Lupus"},{"key":"1013_CR8","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1176\/ajp.134.7.798","volume":"134","author":"MI Good","year":"1977","unstructured":"Good MI, Shader RI. Behavioral toxicity and equivocal suicide associated with chloroquine and its derivatives. Am J Psychiatry. 1977;134:798\u2013601.","journal-title":"Am J Psychiatry"},{"key":"1013_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s40800-017-0048-x","volume":"4","author":"C Manzo","year":"2017","unstructured":"Manzo C, Gareri P, Castagna A. Psychomotor agitation following treatment with hydroxychloroquine. Drug Saf Case Rep. 2017;4:6.","journal-title":"Drug Saf Case Rep"},{"key":"1013_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.psym.2013.06.017","volume":"55","author":"P Das","year":"2014","unstructured":"Das P, Rai A, Chopra A, Philbrick K. Psychosis likely induced by hydroxychloroquine in a patient with chronic Q fever: a case report and clinically relevant review of pharmacology. Psychosomatics. 2014;55:409\u201313.","journal-title":"Psychosomatics"},{"key":"1013_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42:409\u201319.","journal-title":"Drug Inf J"},{"key":"1013_CR12","unstructured":"UMC | VigiBase. https:\/\/www.who-umc.org\/vigibase\/vigibase\/. Accessed 4 Mar 2020"},{"key":"1013_CR13","unstructured":"MedDRA MSSO Welcome. https:\/\/www.meddramsso.com\/. Accessed 4 June 2013"},{"issue":"2","key":"1013_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"issue":"18","key":"1013_CR15","first-page":"1824","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824\u201336.","journal-title":"JAMA"},{"key":"1013_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"J-L Faillie","year":"2019","unstructured":"Faillie J-L. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74:225\u201332.","journal-title":"Therapie"},{"key":"1013_CR17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30:891\u20138.","journal-title":"Drug Saf"},{"key":"1013_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1013_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.08.02","author":"T Fiolet","year":"2020","unstructured":"Fiolet T, Guihur A, Rebeaud M, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis. Clin Microbiol Infect. 2020. https:\/\/doi.org\/10.1016\/j.cmi.2020.08.02 (Epub 26 Aug 2020).","journal-title":"Clin Microbiol Infect."},{"key":"1013_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.therap.2020.05.002","volume":"75","author":"A G\u00e9rard","year":"2020","unstructured":"G\u00e9rard A, Romani S, Fresse A, Viard D, Parassol N, Granvuillemin A, et al. \u201cOff-label\u201d use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie. 2020;75:371\u20139.","journal-title":"Therapie"},{"key":"1013_CR21","doi-asserted-by":"crossref","unstructured":"Drew J. Concerning the side effects of antimalarial drugs used in the extended treatment of rheumatic disease. Med J Aus. 1962;618\u201320.","DOI":"10.5694\/j.1326-5377.1962.tb20626.x"},{"key":"1013_CR22","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10787-018-0498-5","volume":"26","author":"A Mascolo","year":"2018","unstructured":"Mascolo A, Berrino PM, Gareri P, Castagna A, Capuano A, Manzo C, et al. Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. Inflammopharmacology. 2018;26:1141\u20139.","journal-title":"Inflammopharmacology"},{"key":"1013_CR23","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0151-9638(04)93642-3","volume":"131","author":"V Ferraro","year":"2004","unstructured":"Ferraro V, Mantoux F, Denis K, Lay-Macagno M-A, Ortonne J-P, Lacour J-P. Hallucinations during treatment with hydrochloroquine. Ann Dermatol Venereol. 2004;131:471\u20133 (in French).","journal-title":"Ann Dermatol Venereol"},{"key":"1013_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497\u2013506.","journal-title":"Lancet"},{"key":"1013_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/9781118820186.ch10","volume-title":"Mann\u2019s pharmacovigilance","author":"JK Aronson","year":"2014","unstructured":"Aronson JK. Case reports as evidence in pharmacovigilance. Mann\u2019s pharmacovigilance. New York: Wiley; 2014. p. 121\u201337."},{"key":"1013_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.therap.2017.02.005","volume":"72","author":"JK Aronson","year":"2017","unstructured":"Aronson JK. Post-marketing drug withdrawals: pharmacovigilance success, regulatory problems. Therapie. 2017;72:555\u201361.","journal-title":"Therapie"},{"key":"1013_CR27","unstructured":"Center for Drug Evaluation and Research. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. FDA. 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or. Accessed 25 June 2020"},{"key":"1013_CR28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/pds.3622","volume":"23","author":"P de Boissieu","year":"2014","unstructured":"de Boissieu P, Kanagaratnam L, Abou Taam M, Roux M-P, Dram\u00e9 M, Trenque T. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2014;23:989\u201392.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-01013-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-01013-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-01013-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T07:34:01Z","timestamp":1634628841000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-01013-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1013"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-01013-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]},"assertion":[{"value":"30 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Philippe Garcia, Alexis Revet, Antoine Yrondi, Vanessa Rousseau, Yannick Degboe, and Fran\u00e7ois Montastruc have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This work was performed during the university research period of the authors, using the database that is available without fees in the department of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"According to the French law, review from an ethics committee was not necessary for this type of pharmacovigilance study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Because all data in VigiBase are anonymized, patient informed consent is also not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Anonymized data can be made available to investigators upon request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Dr. Fran\u00e7ois Montastruc had full access to all of the data in this study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Philippe Garcia and Fran\u00e7ois Montastruc. Acquisition, analysis, or interpretation of the data: All authors. Drafting of the manuscript: Fran\u00e7ois Montastruc. Critical revision of the manuscript for important intellectual content: All authors. Statistical analyses: Vanessa Rousseau. Supervision: Fran\u00e7ois Montastruc.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}